Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Arbidol prevents COVID-19 infections in health professionals

Stephen Padilla
29 Jun 2020

Prophylactic oral arbidol appears to reduce infection with SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), among frontline health professionals, suggests a study.

“[A]rbidol was associated with a lower incidence of SARS-CoV-2 infection but not hospitalization rate in health professionals, providing a basis for the selection of prophylactic drugs for high-risk populations,” including family members of COVID-19 patients and infectious disease control personnel,” the researchers said.

This study included frontline health professionals diagnosed with COVID-19 before 9 February 2020 in Tongji Hospital, Wuhan, China, as well as control participants in the uninfected group. The researchers obtained clinical and laboratory data with standardized forms.

Of the 164 participants (median age, 37 years; 101 females) enrolled in this study, 82 belonged to the infected group and 82 to the uninfected group. Arbidol was administered to 19 patients (23.2 percent) in the infected group and 48 (58.5 percent) in the uninfected group (odds ratio [OR], 0.214, 95 percent confidence interval [CI], 0.109–0.420). [Public Health Front 2020;doi:10.3389/fpubh.2020.00249]

The cumulative uninfected rate of health professionals was significantly higher in the arbidol than in the nonarbidol group (log-ran test, χ2 = 98.74; p<0.001).

More than half of the patients (n=48; 58.5 percent; median age, 39 years) in the infected group were hospitalized, seven (14.6 percent) of whom were given oral arbidol. Thirty-four patients (41.5 percent; median age, 34 years) with mild symptoms received treatment outside the hospital, 12 (35.3 percent) of whom were prophylactically administered arbidol.

Age (p=0.024) and oral arbidol administration (OR, 0.313, 95 percent CI, 0.108–0.909) were significantly associated with hospitalization rate. In the age-matched case-control study, however, the hospitalization rate did not correlate with arbidol administration (p=0.091).

“It is worth noting that this study found preventative oral arbidol was not significantly associated with the hospitalization rate and duration of positive throat swab of health professionals with COVID-19,” the researchers said. “Moreover, no statistical correlation between prophylactic medication and severe pneumonia, which was worth further consideration.”

This was potentially explained by arbidol’s effectiveness in preventing the virus from entering host cells and blocking the initial stages of the virus’s pathogenic process, which resulted in preventive protection. However, this protective effect was limited when several viruses replicate in host cells. [Curr Med Chem 2008;15:997-1005; Antiviral Res 2014;107:84-94]

“It should be noted that preventative oral arbidol was more common among nonhospitalized patients (35 percent vs 15 percent), although this difference was not significant after matching with age (p=0.091),” the researchers said, adding that further research is needed to establish the role and mechanism of arbidol in SARS-CoV-2 infections.

A broad-spectrum antiviral drug, arbidol blocks the contact, adhesion, and fusion of viral lipid capsules and host cell membranes and prevents replication of the virus. In addition, earlier trials found inhibitory effects of arbidol on several respiratory viruses, including enveloped and unenveloped viruses as well as RNA and DNA viruses. [Vopr Virusol 2008;53:9-13; Curr Med Chem 2008;15:997-1005; Antiviral Res 2014;107:84-94]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.